Confo Therapeutics - About the company
Confo Therapeutics is a series B company based in Brussels (Belgium), founded in 2015. It operates as a Drug discovery technology based on G-protein-coupled receptors (GPCRs). Confo Therapeutics has raised $106M in funding from investors like Wellington Partners Venture Capital, BioGeneration Ventures and Ackermans & van Haaren.
Company Details
Confo Therapeutics a spin-off from the Vrije Universiteit Brussel and VIB is a drug discovery company building a portfolio of products for multiple diseases. Its pipeline drugs based on its proprietary Confo technology. The technology locks inherent unstable functional confirmations of GPCR and this claimed to act as a starting point for drug discovery and it is a tool for selectively stabilization of specific conformational states of membrane proteins.
Key Metrics
Founded Year
2015
Location
Brussels, Belgium
Stage
Series B
Total Funding
$106M in 6 rounds
Latest Funding Round
Investors
Annual Revenue
€1M - €10M as on Dec 31, 2024
Employee Count
81 as on Jul 31, 2026
Legal entities associated with Confo Therapeutics
Confo Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CONFO THERAPEUTICS CIN: 0632.474.939 , Belgium, Active | Jun 10, 2015 | €1M - €10M (As on Dec 31, 2024) | 59 (As on Dec 31, 2022) | - |
Sign up to download Confo Therapeutics' company profile
Confo Therapeutics's funding and investors
Confo Therapeutics has raised a total funding of $106M over 6 rounds. Its first funding round was on Feb 02, 2016. Its latest funding round was a Series B round on Jul 26, 2024 for $*****. 13 investors participated in its latest round. Confo Therapeutics has 16 institutional investors.
Here is the list of recent funding rounds of Confo Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 26, 2024 | 3760810 | Series B | 1022981 | 3218661 | 8827314 | 7772925 |
Mar 28, 2024 | 3829948 | Grant (prize money) | 2981247 | 3466625 | 2250186 | |
Mar 30, 2021 | 2864022 | Grant (prize money) | 5650706 | 5814177 | 6003874 |
Access funding benchmarks and valuations. Sign up today!View details of Confo Therapeutics's funding rounds and investors
Confo Therapeutics' founders and board of directors
Founder? Claim ProfileConfo Therapeutics' employee count trend
Confo Therapeutics has 81 employees as of Jul 26. Here is Confo Therapeutics's employee count trend over the years:
Uncover Confo Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Confo Therapeutics's Investments and acquisitions
Confo Therapeutics has made no investments or acquisitions yet.
News related to Confo Therapeutics
Filter this listMedia has covered Confo Therapeutics for a total of 3 events in the last 1 year, 3 of them have been about company updates.
•
•
•
Confo Therapeutics Receives VLAIO Grant for Ultra-Long-Acting Antibody DevelopmentGlobeNewswire•Oct 08, 2025•Confo Therapeutics
•
•
Confo Therapeutics’ €60m Series B Funding RoundGlobal Legal Chronicle•Aug 23, 2024•NautaDutilh, Confo Therapeutics
•
•
•
Confo Therapeutics Appoints Stephen Dowd as Chief Business OfficerBusiness Wire•Sep 12, 2023•Confo Therapeutics
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Confo Therapeutics
Explore our recently published companies
- Shop Wafi - Jeddah based, 2015 founded, Deadpooled company
- Bixabotanical - Mumbai based, 2015 founded, Unfunded company
- Benhurconstruction - Unfunded company
- Saalfo Tech - Mysuru based, 2016 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - Mumbai based, 2023 founded, Unfunded company
